Sonus, OncoGenex Merge Into Specialty Oncology Company
This article was originally published in The Pink Sheet Daily
Executive Summary
Combined company will have three drugs in clinical development, including lead candidate OGX-011 in Phase II for prostate cancer.
You may also be interested in...
H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
Isis, Alnylam: More Serious Dating, But Still No Marriage
Latest collaboration involves the next step in RNAi research: single-stranded inhibitors against multiple disease targets.
Isis, Alnylam: More Serious Dating, But Still No Marriage
Latest collaboration involves the next step in RNAi research: single-stranded inhibitors against multiple disease targets.